Helix Genomics Pvt. Ltd. (Helix), a Bio-computational research based company focused on providing cutting edge services in biological research and analysis, is planning to take up major projects from abroad.
The company is now all set to become a global player by providing comprehensive bio-computational solutions to address the most complex biological problems. "Our services are with strong technology interface and add research value to the Biotech and Pharmaceutical industry", according to Mohan RK Nimmagadda, CEO, Helix.
The company's competency lies in algorithm-oriented biological programming and providing solutions for the most complex biological queries. It utilizes its in-depth biological and disease knowledge to discover novel biological pathways of diseases and for drug target identification. It uses in-house technologies, and takes up custom design from novel algorithms to specific molecular targets in drug discovery, industrial enzymes and protein engineering. Helix also undertakes services emerging from the vast explosion of biological data like Micro Array data analysis and provides efficient answers to the biological query.
All the contract research services are offered using in-house and patented genomics and computational platforms and products. This allows Helix to benchmark its technologies and services against the international standards. This also allows it to further cut down the cost of contract research and pass on the benefits its clients.
"The company is focusing on areas such as Sequence and Structural Genomics, Disease gene discovery & Bio-Nano machine design, Homology modeling and Drug discovery", Mohan added.
Helix's in-house technologies developed and patented in USA/ EU include- Biological Operating System (BOS) which is 1st of its kind Object Oriented Biological Programming Environment used in biological data analysis. Macromolecule Architectural Component System (MACS), a novel methodology for engineering new targets, sensitive regions of functional importance, nano-molecule design and development. Novel Oncogene Database (OncoBase) which has used novel genetic parameters to develop comprehensive oncological database of biological significance for new drug target identifications. Protein Interaction Mapping Technology (PIMTECH), which is an innovative algorithm developed to identify and comprehend protein-protein interactions leading to knowledge base for developing new therapeutic inventions and interventions.